drugset / Trial / NCT07256964
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for patients with triple-negative breast cancer.
Timeline
- Start
- 2025-11-26
- Primary completion
- 2028-12-31
- Completion
- 2033-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Albumin paclitaxel | Unknown | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Epirubicin | Small molecule | — | — |
| Background | Toripalimab | Monoclonal antibody | 240 mg | — |